COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,800 Articles (22,527 medRxiv, 8,273 bioRxiv)

Most recent first Previous |  Page 846: Articles 8451-8460  | Next

Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
Puga Gomez, R., Ricardo Delgado, Y., Rojas Iriarte, C., Cespedes Henriquez, L., Bello, M. P., Bello, M. P., Vega Mendoza, D. L., Pestana Perez, N., Paredes-Moreno, B., Rodriguez Gonzalez, M., Valenzuela-Silva, C., Sanchez-Ramirez, B., Rodriguez-Noda, L., Perez Nicado, R., Gonzalez-Mugica, R., Hernandez-Garcia, T., Fundora-Barrios, T., Dubet Echevarria, M., Enriquez-Puertas, J. M., Infante Hernandez, Y., Palenzuela-Diaz, A., Gato Orozco, E., Chappi-Estevez, Y., Francisco-Perez, J. C., Suarez Martinez, M., Castillo-Quintana, I. C., Fernandez-Castillo, S., Climent-Ruiz, Y., Santana-Mederos, D., Garcia-Vega, Y., Toledo-Romani, M. E., Valdes-Balbin, Y., Garcia Rivera, D., Verez-Bencomo, v., SOBERANA Research Group.
10.1101/2022.03.03.22271313 — Posted: 2022-03-06
Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21
Lucinde, R. K., Mugo, D., Bottomley, C., Karani, A., Gardiner, E., Aziza, R., Gitonga, J., Karanja, H., Nyagwange, J., Tuju, J., Wanjiku, P., Nzomo, E., Kamuri, E., Thuranira, K., Agunda, S., Nyutu, G., Etyang, A., Adetifa, I. M. O., Kagucia, E., Uyoga, S., Otiende, M., Otieno, E., Ndwiga, L., Agoti, C. N., Aman, R. A., Mwangangi, M., Amoth, P., Kasera, K., Nyaguara, A., Nganga, W., Ochola, L. B., Namdala, E., Gaunya, O., Okuku, R., Barasa, E., Bejon, P., Tsofa, B., Ochola-Oyier, L. I., Warimwe, G. M., Agweyu, A., Scott, J. A. G., Gallagher, K. E.
10.1101/2022.03.03.22271860 — Posted: 2022-03-06
Proteome reveals antiviral host response and NETosis during acute COVID-19 in high-risk patients
Bauer, A., Pachl, E., Hellmuth, J. C., Kneidinger, N., Frankenberger, M., Stubbe, H. C., Ryffel, B., Petrera, A., Hauck, S. M., Behr, J., Kaiser, R., Scherer, C., Deng, L., Teupser, D., Ahmidi, N., Muenchhoff, M., Schubert, B., Hilgendorff, A.
10.1101/2022.03.02.22271106 — Posted: 2022-03-06
Spike mutations of the SARS-CoV-2 Omicron: more likely to occur in the epitopes
Li, H., Chen, Z., Liu, X., Hu, P.
10.1101/2022.03.03.22271159 — Posted: 2022-03-06
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham, S., Toh, Z. Q., Wongprompitak, P., Jansarikit, L., Srisutthisamphan, K., Sapsutthipas, S., Jantraphakorn, Y., Mingngamsup, N., Licciardi, P., Chokephaibulkit, K.
10.1101/2022.03.03.22271601 — Posted: 2022-03-06
Testing Frequency Matters | An Evaluation of the Diagnostic Performance of a SARS-CoV-2 Rapid Antigen Test in United States Correctional Facilities
Lind, M. L., Schultes, O., Robertson, A., Houde, A. J., Cummings, D. A. T., Ko, A. I., Kennedy, B. S., Richenson, R. P.
10.1101/2022.03.03.22271803 — Posted: 2022-03-06
SARS-CoV-2 Seroprevalence among health care workers after the first and second pandemic wave
de Visscher, N., Holemans, X., Gillain, A., Kornreich, A., Lagasse, R., Piette, P., Ventura, M., Thys, F.
10.1101/2022.03.03.22271855 — Posted: 2022-03-06
Development of a COVID-19 risk-assessment model for participants at an outdoor music festival: Evaluation of the validity and control measure effectiveness
Murakami, M., Fujita, T., Li, P., Imoto, S., Yasutaka, T.
10.1101/2022.02.28.22271676 — Posted: 2022-03-06
Evaluation of the role of home rapid antigen testing to determine isolation period after infection with SARS-CoV-2
Cosimi, L., Kelly, C., Esposito, S., Seitz, S., Sher-Jan, C., Turcinovic, J., Friedman, K., Nashed, M., Souweine, J., Fitzgerald, N., Gabriel, S., Connor, J., Hung, D.
10.1101/2022.03.03.22271766 — Posted: 2022-03-06
SARS-CoV-2 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3rd mRNA Vaccine Dose
Roeder, A. J., Koehler, M. A., Svarovsky, S., Jasbi, P., Seit-Nebi, A., Gonzalez-Moa, M. J., Vanderhoof, J., Mckechnie, D., Edwards, B. A., Lake, D. F.
10.1101/2022.03.03.22270812 — Posted: 2022-03-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).